SAN DIEGO, Dec. 4, 2014 /PRNewswire/ -- Organovo
Holdings, Inc. (NYSE MKT: ONVO) ("Organovo"), a three-dimensional
biology company focused on delivering breakthrough 3D bioprinting
technology, has been invited to present at the 25th Annual
Oppenheimer Healthcare Conference, which will be held in
New York December 10-11, 2014.
Organovo's Chairman and Chief Executive Officer Keith Murphy will be presenting at 10:55 AM ET on Thursday,
December 11th.
The objective of the Oppenheimer 25th Annual Healthcare
Conference is to provide investors a broad spectrum of public and
private healthcare companies spanning all major sectors of the
healthcare industry, including bio & specialty pharmaceuticals;
biotechnology; medical devices; healthcare facilities; life science
tools and diagnostics; healthcare information technology and
distribution, and healthcare providers and servicers. The
conference will be held at the Crowne Plaza Times Square Manhattan,
1605 Broadway at 49th, New
York, NY.
About Organovo Holdings, Inc.
Organovo designs and creates functional, three-dimensional human
tissues for use in medical research and therapeutic applications.
The Company develops 3D human disease models through internal
development and in collaboration with pharmaceutical and academic
partners. Organovo's 3D human tissues have the potential to
accelerate the drug discovery process, enabling treatments to be
developed faster and at lower cost. The company recently launched
its initial product of the planned exVive3DTM portfolio
offering, a 3D Human Liver Tissue for use in Toxicology and other
preclinical drug testing. Additional products, including a 3D
Kidney Model, are in development with anticipated release for use
in the latter half of calendar year 2016. The company also
actively conducts early research on specific tissues for
therapeutic use in direct surgical applications. In addition to
numerous scientific publications, the Company's technology has been
featured in The Wall Street Journal, Time Magazine, The Economist,
and numerous others. Organovo is changing the shape of medical
research and practice. Learn more at www.organovo.com.
Safe Harbor Statement
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
as that term is defined in the Private Securities Litigation Reform
Act of 1995. Any forward-looking statements contained herein are
based on current expectations, but are subject to a number of risks
and uncertainties. The factors that could cause actual future
results to differ materially from current expectations include, but
are not limited to, risks and uncertainties relating to the
Company's ability to develop, market and sell products based on its
technology; the expected benefits and efficacy of the Company's
products and technology; the market acceptance of the Company's
products; and the Company's business, research, product
development, regulatory approval, marketing and distribution plans
and strategies. These and other factors are identified and
described in more detail in our filings with the SEC, including our
annual report on Form 10-K filed with the SEC on June 10, 2014 and its report on Form 10-Q filed
with the SEC on November 7, 2014, as
well as our other filings with the SEC. You should not place undue
reliance on these forward-looking statements, which speak only as
of the date that they were made. These cautionary statements should
be considered with any written or oral forward-looking statements
that we may issue in the future. Except as required by applicable
law, including the securities laws of the
United States, we do not intend to update any of the
forward-looking statements to conform these statements to reflect
actual results, later events or circumstances or to reflect the
occurrence of unanticipated events.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/organovo-to-present-at-the-25th-annual-oppenheimer-healthcare-conference-300003825.html
SOURCE Organovo Holdings, Inc.